BIOMAT Database Logo BIOMAT Database Logo

[Extensively drug-resistant tuberculosis treated with bedaquiline]. 2023

A López Pérez, and H Navarro Aznarez, and A Pinilla Rello, and J Perales Pascual, and P Arazo Garcés
Ana López Pérez, Servicio de Farmacia Hospitalaria, Hospital Universitario Miguel Servet Paseo Isabel la Católica 1-3, 50009, Zaragoza, Spain. ana-lopez94@hotmail.com.

UI MeSH Term Description Entries
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D054908 Extensively Drug-Resistant Tuberculosis Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC. Tuberculosis, Extensively Drug-Resistant,Extremely Drug-Resistant Tuberculosis,Tuberculosis, Extremely Drug-Resistant,XDR-TB,Drug-Resistant Tuberculoses, Extensively,Drug-Resistant Tuberculoses, Extremely,Drug-Resistant Tuberculosis, Extensively,Drug-Resistant Tuberculosis, Extremely,Extensively Drug Resistant Tuberculosis,Extensively Drug-Resistant Tuberculoses,Extremely Drug Resistant Tuberculosis,Extremely Drug-Resistant Tuberculoses,Tuberculoses, Extensively Drug-Resistant,Tuberculoses, Extremely Drug-Resistant,Tuberculosis, Extensively Drug Resistant,Tuberculosis, Extremely Drug Resistant
D018088 Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS. Tuberculosis, Drug-Resistant,Tuberculosis, MDR,Tuberculosis, Multi-Drug Resistant,Drug-Resistant Tuberculosis,MDR Tuberculosis,Multi-Drug Resistant Tuberculosis,Multidrug-Resistant Tuberculosis,Tuberculosis, Drug Resistant,Tuberculosis, Multi Drug Resistant,Tuberculosis, Multidrug Resistant
D064687 Diarylquinolines A class of quinoline compounds defined by the presence of two aromatic ring structures which are attached via a side chain to carbon 3 of the qunolinyl structure. The two aromatic moieties are typically NAPTHALENE and BENZENE. Several compounds in this class are used as ANTITUBERCULAR AGENTS. Diaryl Quinoline Derivative,Diarylquinoline,Diarylquinoline Derivative,Diaryl Quinoline Derivatives,Diarylquinoline Derivatives,Derivative, Diaryl Quinoline,Derivative, Diarylquinoline,Derivatives, Diaryl Quinoline,Derivatives, Diarylquinoline,Quinoline Derivative, Diaryl,Quinoline Derivatives, Diaryl

Related Publications

A López Pérez, and H Navarro Aznarez, and A Pinilla Rello, and J Perales Pascual, and P Arazo Garcés
First 2 Extensively Drug-Resistant Tuberculosis Cases From Myanmar Treated With Bedaquiline.
August 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
A López Pérez, and H Navarro Aznarez, and A Pinilla Rello, and J Perales Pascual, and P Arazo Garcés
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
September 2016, The European respiratory journal,
A López Pérez, and H Navarro Aznarez, and A Pinilla Rello, and J Perales Pascual, and P Arazo Garcés
Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis.
January 2020, Southern African journal of infectious diseases,
A López Pérez, and H Navarro Aznarez, and A Pinilla Rello, and J Perales Pascual, and P Arazo Garcés
Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman.
October 2017, Emerging infectious diseases,
A López Pérez, and H Navarro Aznarez, and A Pinilla Rello, and J Perales Pascual, and P Arazo Garcés
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
February 2016, The European respiratory journal,
A López Pérez, and H Navarro Aznarez, and A Pinilla Rello, and J Perales Pascual, and P Arazo Garcés
Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient.
January 2014, The European respiratory journal,
A López Pérez, and H Navarro Aznarez, and A Pinilla Rello, and J Perales Pascual, and P Arazo Garcés
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
October 2017, Emerging infectious diseases,
A López Pérez, and H Navarro Aznarez, and A Pinilla Rello, and J Perales Pascual, and P Arazo Garcés
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
November 2016, The European respiratory journal,
A López Pérez, and H Navarro Aznarez, and A Pinilla Rello, and J Perales Pascual, and P Arazo Garcés
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
November 2016, The European respiratory journal,
A López Pérez, and H Navarro Aznarez, and A Pinilla Rello, and J Perales Pascual, and P Arazo Garcés
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
August 2020, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Copied contents to your clipboard!